Position statement on the use of albumin in liver cirrhosis
Cirrhosis is characterized by a prolonged asymptomatic period in which the inflammation persists, increasing as the disease progresses. Proinflammatory cytokines and pro-oxidant molecules are key in the development of organ dysfunction. Cirrhosis progression and worsening of portal hypertension brin...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | inglés |
| Publicado: |
2022
|
| Materias: | |
| Acceso en línea: | http://eprints.uanl.mx/23464/1/23464.pdf |
| _version_ | 1824416892638461952 |
|---|---|
| author | Castro Narro, Graciela Moctezuma Velázquez, Carlos Male Velázquez, Rene Trejo Estrada, Rafael Bosques Padilla, Francisco Javier Moreno Alcántar, Rosalba Rodríguez Hernández, Heriberto Bautista Santos, Aleida Cortez Hernández, Carlos Alejandro Cerda Reyes, Eira Pérez Escobar, Juanita Aldana Ledesma, Juan Manuel Aguirre Valadez, Jonathan Ruiz Velasco, José Antonio Velarde Contreras Omaña, Raul Miranda Zazueta, Godolfino Reyes Bastidas, Monica del Rocío Meza Cardona, Javier Manuel Chávez Tapia, Norberto C. Fernández Pérez, Nicolas Joaquín García Jiménez, Edgar Santino Torre Delgadillo, Aldo |
| author_facet | Castro Narro, Graciela Moctezuma Velázquez, Carlos Male Velázquez, Rene Trejo Estrada, Rafael Bosques Padilla, Francisco Javier Moreno Alcántar, Rosalba Rodríguez Hernández, Heriberto Bautista Santos, Aleida Cortez Hernández, Carlos Alejandro Cerda Reyes, Eira Pérez Escobar, Juanita Aldana Ledesma, Juan Manuel Aguirre Valadez, Jonathan Ruiz Velasco, José Antonio Velarde Contreras Omaña, Raul Miranda Zazueta, Godolfino Reyes Bastidas, Monica del Rocío Meza Cardona, Javier Manuel Chávez Tapia, Norberto C. Fernández Pérez, Nicolas Joaquín García Jiménez, Edgar Santino Torre Delgadillo, Aldo |
| author_sort | Castro Narro, Graciela |
| collection | Repositorio Institucional |
| description | Cirrhosis is characterized by a prolonged asymptomatic period in which the inflammation persists, increasing as the disease progresses. Proinflammatory cytokines and pro-oxidant molecules are key in the development of organ dysfunction. Cirrhosis progression and worsening of portal hypertension bring about bacterial translocation and systemic dissemination via portal circulation of bacterial products, and molecular patterns associated with damage, which exacerbate the systemic Inflammation. Albumin is a molecule that undergoes structural and functional changes as liver damage progresses, affecting its antioxidant, immunomodulatory, oncotic, and endothelial stabilizing properties. Our knowledge of the properties of albumin reveals a molecule with multiple treatment options, capable of targeting several physiopathological aspects of cirrhosis. For the elaboration of the present manuscript on the uses of albumin in liver cirrhosis, several experts in the field of hepatology in Mexico were divided into 5 working groups to summarise and formulate, when appropriate, position statements: 1)pathophysiology of cirrhosis and properties of albumin; 2)proven uses of albumin [large-volume paracentesis, spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS)]; 3)controversial/emerging uses of albumin (long-term use, acute decompensation, liver transplant, non-HRS kidney injury, muscle cramps, non-SBP infections, hyponatremia, encephalopathy); 4)use of albumin in acute-on-chronic liver failure, immunomodulation, and systemic Inflammation; 5)pharmacoeconomics. |
| format | Article |
| id | eprints-23464 |
| institution | UANL |
| language | English |
| publishDate | 2022 |
| record_format | eprints |
| spelling | eprints-234642024-12-09T18:48:13Z http://eprints.uanl.mx/23464/ Position statement on the use of albumin in liver cirrhosis Castro Narro, Graciela Moctezuma Velázquez, Carlos Male Velázquez, Rene Trejo Estrada, Rafael Bosques Padilla, Francisco Javier Moreno Alcántar, Rosalba Rodríguez Hernández, Heriberto Bautista Santos, Aleida Cortez Hernández, Carlos Alejandro Cerda Reyes, Eira Pérez Escobar, Juanita Aldana Ledesma, Juan Manuel Aguirre Valadez, Jonathan Ruiz Velasco, José Antonio Velarde Contreras Omaña, Raul Miranda Zazueta, Godolfino Reyes Bastidas, Monica del Rocío Meza Cardona, Javier Manuel Chávez Tapia, Norberto C. Fernández Pérez, Nicolas Joaquín García Jiménez, Edgar Santino Torre Delgadillo, Aldo RC Medicina Interna, Psiquiatría, Neurología Cirrhosis is characterized by a prolonged asymptomatic period in which the inflammation persists, increasing as the disease progresses. Proinflammatory cytokines and pro-oxidant molecules are key in the development of organ dysfunction. Cirrhosis progression and worsening of portal hypertension bring about bacterial translocation and systemic dissemination via portal circulation of bacterial products, and molecular patterns associated with damage, which exacerbate the systemic Inflammation. Albumin is a molecule that undergoes structural and functional changes as liver damage progresses, affecting its antioxidant, immunomodulatory, oncotic, and endothelial stabilizing properties. Our knowledge of the properties of albumin reveals a molecule with multiple treatment options, capable of targeting several physiopathological aspects of cirrhosis. For the elaboration of the present manuscript on the uses of albumin in liver cirrhosis, several experts in the field of hepatology in Mexico were divided into 5 working groups to summarise and formulate, when appropriate, position statements: 1)pathophysiology of cirrhosis and properties of albumin; 2)proven uses of albumin [large-volume paracentesis, spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS)]; 3)controversial/emerging uses of albumin (long-term use, acute decompensation, liver transplant, non-HRS kidney injury, muscle cramps, non-SBP infections, hyponatremia, encephalopathy); 4)use of albumin in acute-on-chronic liver failure, immunomodulation, and systemic Inflammation; 5)pharmacoeconomics. 2022 Article PeerReviewed text en cc_by_nc_nd http://eprints.uanl.mx/23464/1/23464.pdf http://eprints.uanl.mx/23464/1.haspreviewThumbnailVersion/23464.pdf Castro Narro, Graciela y Moctezuma Velázquez, Carlos y Male Velázquez, Rene y Trejo Estrada, Rafael y Bosques Padilla, Francisco Javier y Moreno Alcántar, Rosalba y Rodríguez Hernández, Heriberto y Bautista Santos, Aleida y Cortez Hernández, Carlos Alejandro y Cerda Reyes, Eira y Pérez Escobar, Juanita y Aldana Ledesma, Juan Manuel y Aguirre Valadez, Jonathan y Ruiz Velasco, José Antonio Velarde y Contreras Omaña, Raul y Miranda Zazueta, Godolfino y Reyes Bastidas, Monica del Rocío y Meza Cardona, Javier Manuel y Chávez Tapia, Norberto C. y Fernández Pérez, Nicolas Joaquín y García Jiménez, Edgar Santino y Torre Delgadillo, Aldo (2022) Position statement on the use of albumin in liver cirrhosis. Annals of hepatology, 27 (4). pp. 1-12. ISSN 1665-2681 http://doi.org/10.1016/j.aohep.2022.100708 doi:10.1016/j.aohep.2022.100708 |
| spellingShingle | RC Medicina Interna, Psiquiatría, Neurología Castro Narro, Graciela Moctezuma Velázquez, Carlos Male Velázquez, Rene Trejo Estrada, Rafael Bosques Padilla, Francisco Javier Moreno Alcántar, Rosalba Rodríguez Hernández, Heriberto Bautista Santos, Aleida Cortez Hernández, Carlos Alejandro Cerda Reyes, Eira Pérez Escobar, Juanita Aldana Ledesma, Juan Manuel Aguirre Valadez, Jonathan Ruiz Velasco, José Antonio Velarde Contreras Omaña, Raul Miranda Zazueta, Godolfino Reyes Bastidas, Monica del Rocío Meza Cardona, Javier Manuel Chávez Tapia, Norberto C. Fernández Pérez, Nicolas Joaquín García Jiménez, Edgar Santino Torre Delgadillo, Aldo Position statement on the use of albumin in liver cirrhosis |
| thumbnail | https://rediab.uanl.mx/themes/sandal5/images/online.png |
| title | Position statement on the use of albumin in liver cirrhosis |
| title_full | Position statement on the use of albumin in liver cirrhosis |
| title_fullStr | Position statement on the use of albumin in liver cirrhosis |
| title_full_unstemmed | Position statement on the use of albumin in liver cirrhosis |
| title_short | Position statement on the use of albumin in liver cirrhosis |
| title_sort | position statement on the use of albumin in liver cirrhosis |
| topic | RC Medicina Interna, Psiquiatría, Neurología |
| url | http://eprints.uanl.mx/23464/1/23464.pdf |
| work_keys_str_mv | AT castronarrograciela positionstatementontheuseofalbumininlivercirrhosis AT moctezumavelazquezcarlos positionstatementontheuseofalbumininlivercirrhosis AT malevelazquezrene positionstatementontheuseofalbumininlivercirrhosis AT trejoestradarafael positionstatementontheuseofalbumininlivercirrhosis AT bosquespadillafranciscojavier positionstatementontheuseofalbumininlivercirrhosis AT morenoalcantarrosalba positionstatementontheuseofalbumininlivercirrhosis AT rodriguezhernandezheriberto positionstatementontheuseofalbumininlivercirrhosis AT bautistasantosaleida positionstatementontheuseofalbumininlivercirrhosis AT cortezhernandezcarlosalejandro positionstatementontheuseofalbumininlivercirrhosis AT cerdareyeseira positionstatementontheuseofalbumininlivercirrhosis AT perezescobarjuanita positionstatementontheuseofalbumininlivercirrhosis AT aldanaledesmajuanmanuel positionstatementontheuseofalbumininlivercirrhosis AT aguirrevaladezjonathan positionstatementontheuseofalbumininlivercirrhosis AT ruizvelascojoseantoniovelarde positionstatementontheuseofalbumininlivercirrhosis AT contrerasomanaraul positionstatementontheuseofalbumininlivercirrhosis AT mirandazazuetagodolfino positionstatementontheuseofalbumininlivercirrhosis AT reyesbastidasmonicadelrocio positionstatementontheuseofalbumininlivercirrhosis AT mezacardonajaviermanuel positionstatementontheuseofalbumininlivercirrhosis AT chaveztapianorbertoc positionstatementontheuseofalbumininlivercirrhosis AT fernandezpereznicolasjoaquin positionstatementontheuseofalbumininlivercirrhosis AT garciajimenezedgarsantino positionstatementontheuseofalbumininlivercirrhosis AT torredelgadilloaldo positionstatementontheuseofalbumininlivercirrhosis |